Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Xencor Inc (NQ: XNCR ) 20.66 -0.18 (-0.86%) Streaming Delayed Price Updated: 11:54 AM EDT, Jul 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Xencor Inc < Previous 1 2 3 Next > Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 December 15, 2021 Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE: Via Benzinga Xencor: Q3 Earnings Insights November 08, 2021 Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor their... Via Benzinga Xencor's Earnings: A Preview May 04, 2021 On Wednesday, May 05, Xencor (NASDAQ:XNCR) will release its latest earnings report. Check out Benzinga's preview to understand the implications. What Are Earnings, Net Income,... Via Benzinga Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal November 27, 2021 In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to... Via Talk Markets Pfizer Sues Former Employee For Stealing Confidential Info On Its Megablockbuster COVID-19 Vaccine November 24, 2021 Pfizer Inc (NYSE: PFE) has sued its former associate director of clinical statistics in a California court to get a handle on allegedly stolen information. The Company's... Via Benzinga Topics Lawsuit Exposures COVID-19 Financial Legal Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma November 22, 2021 Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a... Via Benzinga Novartis Dumps Another Bispecific Candidate From Xencor Deal November 09, 2021 Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The... Via Benzinga Xencor, inc (XNCR) Q3 2021 Earnings Call Transcript November 08, 2021 XNCR earnings call for the period ending September 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Earnings Scheduled For November 8, 2021 November 08, 2021 Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... Via Benzinga Preview: Xencor's Earnings November 05, 2021 Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody October 04, 2021 Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global... Via Benzinga The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration August 27, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Return on Capital Employed Insights for Xencor August 20, 2021 After pulling data from Benzinga Pro it seems like during Q2, Xencor (NASDAQ:XNCR) earned $9.09 million, a 157.98% increase from the preceding quarter. Xencor also posted a total... Via Benzinga Stocks That Hit 52-Week Lows On Friday August 20, 2021 On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) was the largest firm on a market cap basis to set a new 52-... Via Benzinga Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China August 17, 2021 Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater... Via Benzinga Xencor, inc (XNCR) Q2 2021 Earnings Call Transcript August 04, 2021 XNCR earnings call for the period ending June 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies May 25, 2021 Xencor Inc (NASDAQ: XNCR has entered into a technology license agreement with Bristol-Myers Squibb Co (NYSE: BMY), under which BMY will have non-exclusive access... Via Benzinga Exposures COVID-19 Xencor Inc (XNCR) Q1 2021 Earnings Call Transcript May 06, 2021 XNCR earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings August 04, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... Via Benzinga Earnings Scheduled For August 4, 2021 August 04, 2021 Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to... Via Benzinga The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs August 01, 2021 Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... Via Benzinga Exposures Product Safety The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex April 20, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,... Via Benzinga The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split April 15, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ... Via Benzinga Exposures COVID-19 < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.